BUSINESSWIRE · 2026-11-05 12:00 UTC

Caldera Therapeutics Reports New CLD-423 Phase 1a Data and Expands Immunology and Inflammation Pipeline With Anti IL-17 X TL1A Bispecific Antibody Program

Caldera Therapeutics reported Phase 1a data for CLD-423 showing favorable tolerability, immunogenicity, and sustained target engagement in 56 healthy subjects, supporting planned Phase 2 trials in ulcerative colitis and Crohn's disease in early 2027. The company licensed an exclusive worldwide agreement with Qyuns Therapeutics for a preclinical IL-17 x TL1A bispecific antibody program to expand its pipeline for immune-mediated diseases. CLD-423 demonstrated no dose-limiting toxicities, with most adverse events mild and unrelated to treatment; low infectious event rates were observed.

Loading the story on Tree News…